Jaguar Health FY26 Q2 net loss narrows 80.7% to USD 4.08 million; revenue rises 314% to USD 21.5 million
JAGX•JAGX•JAGX•JAGX•Jaguar Health posted a net loss of USD 4.08 million for the six months ended June 30, 2026, narrowing 80.7%.
Revenue climbed to USD 21.5 million, up 314%, driven by USD 19.09 million of license revenue.
Product revenue fell to USD 2.39 million, down 53.3%, reflecting lower Mytesi volume following the January 2026 Woodward licensing deal.
Operating income turned positive at USD 2.59 million, versus an operating loss in the prior-year period.
Cash was USD 3.8 million at June 30, 2026; management said the January 2026 upfront fees did not remove going-concern doubt.
